Arctic Bioscience – Q4 2023 Operational update – Foundation for an exciting 2024
Highlights Q4 2023: · The HeROPA clinical trial fully recruited in January 2024 · Available liquidity end of 2023 of NOK 109,6 million · Agreement on debt funding of NOK 65 million to finance new inhouse manufacturing line · Total revenues from the nutraceutical business impacted by movement in customer’s delivery plans into 2024 and manufacturing delays · Positive order backlog for 2024 for the nutraceutical business · 2023 adjusted EBITDA in line with expectations and according to earlier guided range2023 has been an eventful year for Arctic Bioscience, culminating in